GHRP-2 | Pen

GHRP-2 is a peptide positioned for controlled research settings where ghrelin receptor (GHS-R1a) signaling is being studied in relation to pulsatile growth hormone release, IGF-1 axis outputs, and neuroendocrine/metabolic readouts.

Supports

1. High-amplitude GH pulse generation (timing- and model-dependent)
2. Downstream IGF-1 and IGF-binding protein profiles (endpoint-based)
3. GHS-R1a-driven intracellular calcium signaling readouts (PLC/IP3-linked)
4. Hypothalamic–pituitary axis integration markers (somatostatin/GHRH balance)
5. Appetite and substrate-utilization endpoints tracked in human and preclinical studies

Description

GHRP-2 (also referred to in the literature as KP-102 or pralmorelin) is a synthetic growth hormone secretagogue studied for its ability to stimulate endogenous growth hormone (GH) release through activation of the ghrelin receptor, GHS-R1a. Unlike GHRH analogs that primarily act via pituitary GHRH receptors, GHRP-2 is used to probe GHS-R1a-mediated secretagogue signaling and its interaction with broader hypothalamic–pituitary regulatory networks.

In experimental endocrinology, GHRP-2 is frequently selected when researchers want robust, measurable GH pulse responses with preserved feedback dynamics. Study endpoints often include GH pulsatility metrics, downstream IGF-1/IGFBP profiles, and protocol-specific metabolic or behavioral measures (e.g., appetite-related readouts) where ghrelin-pathway engagement is a variable of interest.

GHRP-2 is positioned strictly for laboratory research, with outcomes interpreted as model-dependent signals rather than therapeutic claims.

Clinical Status

Human studies of GHRP-2 include controlled designs assessing endocrine outputs (GH, and in some protocols prolactin/ACTH/cortisol) as well as metabolic/appetite endpoints. Preclinical and in vitro literature further characterizes receptor signaling and downstream pathways. These data do not indicate regulatory approval for medical use.

Evidence type:
Human RCT ▣ | Observational ▣ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

GHRP-2 is studied as an agonist of GHS-R1a, a GPCR expressed in hypothalamic and pituitary tissues. Receptor activation is linked to intracellular signaling that prominently includes phospholipase C (PLC) activation, IP3 generation, and calcium mobilization—pathways commonly used as mechanistic readouts for GH secretagogues in cellular and tissue models.

At the systems level, GHRP-2 is investigated for dual-site effects that can involve direct stimulation of pituitary somatotroph activity and modulation of hypothalamic circuits that regulate GH pulsatility (including interactions with GHRH and somatostatin tone). In some protocols, ancillary endocrine readouts (e.g., ACTH/cortisol or prolactin) are monitored to characterize broader neuroendocrine engagement in a study-dependent manner.

Benefits

• Generates high-amplitude growth hormone pulses:
  GHRP-2 is recognized for producing stronger growth hormone peaks compared to earlier GHRPs. By binding to the GHS-R1a receptor, it increases intracellular calcium signaling within pituitary somatotroph cells, triggering GH exocytosis. The resulting hormone release follows a pulsatile rhythm rather than constant elevation. Higher pulse amplitude is associated with stronger downstream IGF-1 signaling in experimental models. This amplified pulsatility differentiates GHRP-2 from milder secretagogues and supports its positioning in anabolic hormone research.
• Enhances the GH–IGF-1 endocrine cascade:
  Once GH is released, it stimulates hepatic production of IGF-1. IGF-1 then activates the PI3K/Akt pathway, leading to mTOR engagement and increased protein synthesis. Through this cascade, GHRP-2 indirectly influences cellular growth and structural adaptation. The sequential endocrine layering preserves physiological hierarchy, ensuring that peripheral tissues respond to naturally released hormones rather than direct receptor agonism.
• Strong ghrelin receptor affinity and dual-site activation:
  GHRP-2 binds to ghrelin receptors expressed both in the hypothalamus and pituitary. Hypothalamic activation enhances GHRH neuron activity while suppressing somatostatin tone, which normally inhibits GH release. Simultaneously, pituitary receptor activation directly stimulates hormone secretion. This coordinated dual-site engagement increases both frequency and amplitude of GH pulses.
• Influences intracellular anabolic signaling pathways:
  Elevated GH and IGF-1 levels activate intracellular pathways responsible for protein assembly and cellular growth. Akt phosphorylation promotes cell survival and inhibits apoptotic signaling. mTOR activation increases ribosomal protein translation and muscle fiber adaptation. These intracellular changes support sustained anabolic signaling environments in controlled research settings.
• Supports muscle recovery and structural adaptation:
  Growth hormone influences collagen synthesis, connective tissue remodeling, and muscle repair signaling. By stimulating endogenous GH release, GHRP-2 activates repair-associated endocrine pathways. IGF-1 contributes to satellite cell activation and differentiation, supporting structural muscle adaptation in laboratory models.
• Moderate appetite pathway engagement compared to GHRP-6:
  Although GHRP-2 activates the same ghrelin receptor as GHRP-6, appetite stimulation tends to be less pronounced. Hypothalamic neuropeptide Y signaling may still be influenced, but the primary observed effect is GH amplification. This distinction positions GHRP-2 as a more hormone-focused secretagogue rather than a hunger-driven peptide.
• Integrates with broader hypothalamic-pituitary networks:
  Activation of the ghrelin receptor influences interconnected neuroendocrine circuits. Experimental observations suggest mild ACTH modulation due to hypothalamic cross-talk. This broader endocrine integration reflects the complexity of central hormone regulation and differentiates GHRP-2 from highly selective secretagogues.
• Creates cumulative anabolic exposure over repeated pulses:
  Repeated amplification of GH pulses increases cumulative IGF-1 exposure. This sustained endocrine environment enhances activation of growth-related intracellular pathways. Over time, continued pulsatile stimulation may promote adaptive signaling responses within tissues studied in anabolic research models.
• Preserves endogenous feedback regulation:
  Because GHRP-2 stimulates natural hormone release rather than supplying exogenous GH, hypothalamic feedback loops remain active. Somatostatin release continues to regulate pulse frequency, maintaining physiological control. This preservation of feedback integrity is important in long-term endocrine modulation research.
  

Research Data

Stack Suggestions

In extended experimental designs, GHRP-2 is sometimes paired with:

• CJC-1295 (No-DAC) → dual-route GH pulse studies (GHRH receptor + GHS-R1a)
• Ipamorelin → comparative ghrelin-receptor secretagogue profiling within the same protocol framework
• NAD+ → mitochondrial/energy endpoints sometimes tracked alongside endocrine rhythm variables

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

Side effects in GHRP-2 research can be model-, population-, and protocol-dependent. Human studies and clinical testing paradigms commonly include tolerability monitoring and may report transient effects such as flushing, headache, or local reactions, alongside protocol-dependent shifts in endocrine markers (e.g., prolactin and ACTH/cortisol). This product is positioned for controlled research use only, and outcomes should be interpreted within the study’s monitoring framework.

Scientific References

• Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men — Human RCT
• Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man — Human
• Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide — Animal/In vitro
• The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GRF receptor antagonist — In vitro
• ACTH releasing activity of KP-102 (GHRP-2) in rats is mediated mainly by release of CRF — Animal
• Evaluation of Hypothalamic–Pituitary–Adrenal Axis by the GHRP2 Test: Comparison With the Insulin Tolerance Test — Human
• Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure — Human
• The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation — Review
• From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation — Review
• Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN — Review

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.